for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Dynavax Technologies Corporation

DVAX.OQ

Latest Trade

--

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

--

 - 

--

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
--
Open
--
Volume
--
3M AVG Volume
25.16
Today's High
--
Today's Low
--
52 Week High
--
52 Week Low
--
Shares Out (MIL)
83.87
Market Cap (MIL)
478.03
Forward P/E
-2.81
Dividend (Yield %)
--

Next Event

Q4 2019 Dynavax Technologies Corp Earnings Release

Latest Developments

More

Dynavax Announces Third Quarter 2019 Financial Results

Dynavax Technologies Announces Proposed Public Offering Of Common Stock, Non-Voting Preferred Stock And Warrants To Purchase Common Stock

Dynavax Technologies Q2 Loss Per Share $0.66

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.

Industry

Biotechnology & Drugs

Contact Info

2929 7th St Ste 100

+1.510.8485100

http://www.dynavax.com/

Executive Leadership

Arnold L. Oronsky

Independent Chairman of the Board

David F. Novack

Interim Co-President, Co-Principal Executive Officer

Ryan Spencer

Interim Co-President, Co-Principal Executive Officer

Michael S. Ostrach

Chief Financial Officer, Senior Vice President, Chief Business Officer

Robert Janssen

Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs

Key Stats

1.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.920

2017

-1.790

2018

-2.550

2019(E)

-2.028
Price To Earnings (TTM)
--
Price To Sales (TTM)
15.95
Price To Book (MRQ)
12.21
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
453.61
LT Debt To Equity (MRQ)
453.61
Return on Investment (TTM)
-67.82
Return on Equity (TTM)
-57.99

Latest News

Latest News

BRIEF-Dynavax Reports Q1 Loss Per Share Of $0.63

* Q1 EARNINGS PER SHARE VIEW $-0.49 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Dynavax Technologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

* DYNAVAX TECHNOLOGIES CORPORATION ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Source text for Eikon: Further company coverage:

BRIEF-Dynavax Provides New Durability Of Response Data For SD-101 In Combination With Keytruda In Melanoma

* DYNAVAX PROVIDES NEW DURABILITY OF RESPONSE DATA FOR SD-101 IN COMBINATION WITH KEYTRUDA (PEMBROLIZUMAB) IN MELANOMA AT THE 2018 AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING

BRIEF-Dynavax Qtrly Loss Per Share $0.45

* DYNAVAX REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS

BRIEF-Dynavax Secures $175 Million In Non-Dilutive Debt Financing

* DYNAVAX SECURES $175 MILLION IN NON-DILUTIVE DEBT FINANCING

BRIEF-Dynavax Says Heplisav-B Available In U.S. For Prevention Of Hepatitis B In Adults

* DYNAVAX ANNOUNCES HEPLISAV-B™ IS NOW AVAILABLE IN THE UNITED STATES FOR THE PREVENTION OF HEPATITIS B IN ADULTS Source text for Eikon: Further company coverage:

Dynavax's hepatitis B vaccine gets FDA nod on third try, shares up

Dynavax Technologies Corp's hepatitis B vaccine won the U.S. Food and Drug Administration's approval on the third attempt and Chief Executive Eddie Gray told Reuters the company was open to, but not waiting for, a partner to market the drug.

BRIEF-Dynavax says FDA approves Heplisav-B for Hepatitis B prevention in adults

* Dynavax announces FDA approval of Heplisav-B for prevention of Hepatitis B in adults

Dynavax Hep B vaccine gets FDA approval

Dynavax Technologies Corp's twice-rejected hepatitis B vaccine was approved by the U.S. Food and Drug Administration on Thursday, marking the drug developer's first regulatory approval.

BRIEF-Dynavax reports Q3 loss per share $0.38

* Q3 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S

BRIEF-Dynavax initiates clinical trial in non-small cell lung cancer with a novel inhaled TLR9 Agonist

* Dynavax initiates clinical trial in non-small cell lung cancer with a novel inhaled TLR9 Agonist in combination with Anti-PD-1 therapy

Exclusive: Immunotherapy developer Dynavax explores options for Hepatitis B drug-sources

Dynavax Technologies Corporation, a biotechnology company focused on drugs that harness the immune system to combat disease, is reviewing strategic options for its hepatitis B vaccine, which could include a potential sale or licensing deal, people familiar with the matter...

BRIEF-Dynavax Technologies says ‍on August 21 court entered an order preliminarily approving a proposed settlement​

* Dynavax Technologies Corp says on August 21 court entered an order preliminarily approving a proposed settlement

BRIEF-Vectura says global development agreement with Dynavax

* VECTURA'S AKITA SMART NEBULISER TO BE USED BY DYNAVAX TO DELIVER DV281

BRIEF-Dynavax announces exercise in full of over-allotment option

* Dynavax announces exercise in full of over-allotment option and completion of public offering of common stock Source text for Eikon: Further company coverage:

BRIEF-Dynavax announces proposed public offering of common stock

* Dynavax Technologies Corp - intends to offer and sell $125.0 million of shares of its common stock

BRIEF-Dynavax provides U.S. regulatory update on heplisav-b following FDA advisory committee meeting

* Dynavax provides U.S. regulatory update on heplisav-b(tm) following fda advisory committee meeting

BRIEF-Dynavax reports Q2 loss per share $0.41

* Q2 earnings per share view $-0.45 -- Thomson Reuters I/B/E/S

Data supports safety of Dynavax hepatitis B vaccine: U.S. FDA panel

Available data supports the safety of Dynavax Technologies Corp's experimental hepatitis B vaccine when administered to adults, a panel of expert advisers to the U.S. Food and Drug Administration said on Friday.

BRIEF-Dynavax announces FDA advisory committee vote in favor of Heplisav-B

* Dynavax announces FDA advisory committee vote in favor of Heplisav-B (tm)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up